Crizanlizumab for sickle cell pain crises
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial tests whether crizanlizumab can reduce painful sickle cell crises (called vaso-occlusive crises or VOCs) in people with sickle cell disease who have frequent crises. It may be an option for those who still have crises despite current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years or older.
- You have been diagnosed with sickle cell disease (any type).
- You have had 4 to 12 painful crises that needed medical attention in the last 12 months.
- If you take hydroxyurea or similar treatments, you have been on a stable dose for at least 3 months.
- You have not had a stroke or brain bleed in the past year.
- You are not on a chronic blood transfusion program.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral medicine called rilzabrutinib to see if it can reduce painful episodes in people with sickle-cell disease. It may be an option if you have regular pain crises and are looking for a new treatment.
This study lets people with sickle cell disease who already finished a Novartis crizanlizumab trial continue treatment under a rollover plan. It’s designed for participants who benefited from crizanlizumab and completed the earlier study schedule without major ongoing side effects.
This study tests an experimental pill called etavopivat for people with sickle cell disease who have had some pain crises in the past year. The goal is to see if it reduces these crisis episodes.
This early trial tests crizanlizumab (a medicine for sickle cell) to see if it improves how your body matches oxygen supply with oxygen needs. It may be helpful for reducing sickle-cell–related complications by changing blood vessel and oxygen behavior.
This trial tests if an intravenous medication called L-citrulline can help treat pain crises in children and young adults with sickle cell disease. Participants receive either the study drug or a placebo while in the hospital for a severe pain episode.
This trial tests an IV medication called L-citrulline for children, teens, and young adults (ages 6–21) with sickle cell disease who are having a sudden, severe pain crisis (called a vaso-occlusive crisis). The goal is to see if it helps relieve pain quickly.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.